Cormedix Inc. ((CRMD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cormedix Inc. is conducting an open-label study titled ‘An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter.’ The study aims to evaluate the safety and efficacy of DefenCath®, a catheter lock solution, in preventing bloodstream infections in pediatric patients undergoing hemodialysis.
The intervention being tested is DefenCath®, a catheter lock solution composed of taurolidine and heparin, designed to prevent catheter-related bloodstream infections. This solution is compared against the institutional standard of care.
The study is interventional, with a randomized and parallel assignment model. It is unmasked, meaning both the researchers and participants know which treatment is being administered. The primary purpose of the study is prevention.
The study began on July 8, 2025, with an estimated primary completion date yet to be announced. The last update was submitted on August 13, 2025. These dates are crucial for tracking the study’s progress and potential impacts on regulatory approvals and market availability.
The study’s outcome could significantly impact Cormedix Inc.’s stock performance, as positive results may enhance investor confidence and market position, particularly in the pediatric nephrology sector. Competitors in the catheter lock solution market will be closely monitoring these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.